Taipei-based precision oncology firm Anbogen Therapeutics Inc. drew $12.5 million in a series A funding round to propel two major clinical assets in its cancer pipeline.
Around 75% of breast cancer cases in postmenopausal patients show estrogen receptor (ER) expression. There is a need for new long-acting formulations for selective estrogen receptor degradation inducers (SERDs) because the efficacy of current options, such as the approved SERD fulvestrant, is limited due to poor solubility and stability.
Phyllodes tumors (PTs) are rare, fibroepithelial tumors of the breast that can arise as benign, borderline or malignant. Little is known about the molecular mechanisms behind their occurrence, and it is easy to misdiagnose them as other histologically similar tumors, such as metaplastic breast cancer. It was hypothesized that DNA methylation could be a helper here.
Chengdu Easton Biopharmaceuticals Co. Ltd. has identified cyclin-dependent kinase 7 (CDK7) inhibitors reported to be useful for the treatment of cancer.
Zentaur Therapeutics USA Inc. has disclosed ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.
Increasing evidence exists suggesting plasma exosomal microRNAs (miRNAs) are involved in tumor progression, but their role in breast cancer is still unknown. Plasma exosome miRNA sequencing revealed that elevated levels of miR-361-3p were significantly correlated with malignant breast cancer progression in patients.
Trioar Inc. has synthesized antibody-drug conjugates comprising antibodies targeting HER2 (Neu, erbB2) covalently linked to cytotoxic drugs (particularly, MMAE and MMAF) through a linker reported to be useful for the treatment of cancer.
Accent Therapeutics Inc. has completed a $75 million series C financing to support progression of its lead programs through early clinical development.
